Compare Eli Lilly And Co (LLY) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Royal Caribbean Cruises Ltd — how do they compare? Eli Lilly And Co trades at $1,159 (market cap $1.02T), while Royal Caribbean Cruises Ltd trades at $285.76 (market cap $76.75B). The key difference: Eli Lilly And Co is far larger — about 13.3× Royal Caribbean Cruises Ltd's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| LLY | RCL | |
|---|---|---|
Market Cap | $1.02T | $76.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $365.84 |
52-Week Low | $625.65 | $246.71 |
Enterprise Value | $1.06T | $98.03B |
Dividend Yield | 0.6% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Royal Caribbean (RCL) trades at $285.59, down 0.48% on the day, with technical indicators showing a neutral to bullish bias as the stock tests support near $285. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by robust revenue growth from $8.8B in 2022 to $17.93B in 2025. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $3.60 surpassing estimates of $3.24.
The investment outlook remains positive given analyst consensus price target of $328 (15% upside), strong cash flow generation, and continued recovery in cruise demand. Key risks include high debt levels ($18.47B long-term debt), sensitivity to economic cycles, and competitive pressures in the cruise industry. The upcoming Q2 2026 earnings report on July 28 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
